Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 8981 results

  1. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  2. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

    Technology appraisal guidance
    Discontinued

  5. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

    Technology appraisal guidance
    Discontinued

  6. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

    Technology appraisal guidance
    Discontinued

  7. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

    Technology appraisal guidance
    Discontinued

  8. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

    Technology appraisal guidance
    Discontinued

  9. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

    Technology appraisal guidance
    Discontinued

  10. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

    NICE guideline
    Discontinued

  11. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued Reference number: GID-TA10193

    Technology appraisal guidance
    Discontinued

  13. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

    Technology appraisal guidance
    Discontinued

  14. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued Reference number: GID-TA10179

    Technology appraisal guidance
    Discontinued

  15. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued Reference number: GID-TA10687

    Technology appraisal guidance
    Discontinued